Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , Nov. 27, 2014 Research ... "Global Palmitic Acid Industry Report 2014" report ... The Global Palmitic Acid Industry Report ... current state of the global palmitic acid industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:11/27/2014)... BELLINGHAM, Washington, and PITTSFIELD, Massachusetts, USA (PRWEB) November 26, ... pinpoint cancer cells with more accuracy, additive systems to ... improve highway safety by analyzing road conditions are among ... Awards for Photonics Innovation . The awards are sponsored ... photonics , and Photonics Media . , Winners ...
(Date:11/26/2014)... 2014 The North America Thermal ... market for detailed analysis of the growth trends ... reach $616.3 million by 2018, growing at a ... Browse through the TOC of the North America ... idea of the in-depth analysis and industry segmentation ...
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... power supply is an all-purpose power supply , Douglas Drake Michelle Cayouette ... , , , ... Supply, Stratagene has developed the new ... power supply for any, electrophoretic application. The SmartPower 4000 power ...
... , , , ,,,, , A time-saving alternative to conventional library plating and screening ... , , ... , Department of Cell Biology, Cleveland Clinic Foundation, , ... , , ...
... powerful method to detect protein interactions in mammalian ... ,Stratagene , With Stratagenes mammalian two-hybrid assay kit, ... interactions via the activation,of reporter gene expression. This ... functional transcription factor caused by the association of,two ...
Cached Biology Technology:A Versatile Power Supply for All Electrophoresis Applications 2A Versatile Power Supply for All Electrophoresis Applications 3A Versatile Power Supply for All Electrophoresis Applications 4A Versatile Power Supply for All Electrophoresis Applications 5Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 2Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 3Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 4Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 5Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 6New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 2New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 3New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 4New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 5New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 6New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 7New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 8New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 9
(Date:11/6/2014)... a predator. Except when that predator runs so fast that ... its size, is the fastest creature on Earth. Some of ... (at about five miles per hour). The fastest human can ... from the tiger beetle, a person would have to hit ... a problem. At peak speeds, everything becomes a blur. They ...
(Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... STATION N.J., PRINCETON, N.J. and JAMAICA PLAIN, Mass., ... (through an affiliate), Medarex, Inc. (NASDAQ: MEDX) and ... Massachusetts Medical School (UMMS) today announced that they ... CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and ...
... Cambridge, UK Wolf-Hirschhorn Syndrome (WHS) is a human ... with WHS have a characteristic set of facial features, ... forehead, and highly arched eyebrows. Other symptoms associated ... and skeletal abnormalities, and the severity of these symptoms ...
... AWRE ) today announced that it has amended and ... of comments and a request from the Securities and Exchange ... range of the tender offer to between $2.20 and $2.60 ... share. Aware has also extended the expiration date for the ...
Cached Biology News:Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 2Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 3Mouse model provides a new tool for investigators of human developmental disorder 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 3Aware, Inc. Amends and Extends Dutch Auction Tender Offer 4
... marker is specifically designed for two-dimensional ... The four proteins in this marker ... diagonal pattern across a 2D gel. ... 3.8. Mol wt: ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
...
Methylation analysis of gene promoters using bilsulfite treatment of DNA and comparative DNA sequence analysis. Probe design and PCR included....
Biology Products: